SynAct Pharma

Third party research2026-07-13 13:02

Synact Pharma: Preclinical resomelagon data support use in osteoarthritis - Edison

SynAct Pharma has reported that some early preclinical data have shown that resomelagon may reduce inflammation and joint damage associated with osteoarthritis, and, hence, may reduce pain and improve quality of life for this patient population. While...

SynAct Pharma

Third party research2026-06-17 10:54

SynAct Pharma’s Phase IIb ADVANCE readout supports Phase III planning - Edison

SynAct has reported top-line results from its Phase IIb ADVANCE study evaluating resomelagon in newly diagnosed, treatment-naïve patients with rheumatoid arthritis. In our view, the readout presents an encouraging dataset despite the study not achieving...

SynAct Pharma

Regulatory press release2026-06-11 13:15

SynAct Pharma

Revenue and EBIT-%

EPS and dividend

Financial calendar

EPS and dividend

Revenue and EBIT-%

EPS and dividend

Financial calendar

Financial calendar

Join Inderes community

Inderes account

EPS and dividend

Financial calendar

Join Inderes community

Inderes account